MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response

Haematologica

Volumn 97, Issue 4, 2012, Pages 586-594

  Wang, Weixin ^a   Corrigan Cummins, Meghan ^a   Hudson, Justin ^b   Maric, Irina ^a   Simakova, Olga ^a   Neelapu, Sattva S ^c   Kwak, Larry W ^c   Janik, John E ^d   Gause, Barry ^e   Jaffe, Elaine S ^d   Calvo, Katherine R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SAIC FREDERICK INC   (United States)

Author keywords

Follicular lymphoma; Lymphomagenesis; MiRNA; Tumor response

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BRCA1 PROTEIN; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLOPHOSPHAMIDE; DOXORUBICIN; DROSHA PROTEIN; E1A ASSOCIATED P300 PROTEIN; EPHRIN RECEPTOR A2; ETOPOSIDE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 1BETA; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; KRUPPEL LIKE FACTOR 4; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PREDNISONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN KINASE C EPSILON; PROTEIN KINASE SYK; PROTEIN SERINE THREONINE KINASE; RAD51 PROTEIN; RIBONUCLEASE III; SUPPRESSOR OF CYTOKINE SIGNALING 2; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GERMINAL CENTER; HUMAN; HUMAN CELL; LYMPH NODE BIOPSY; LYMPHOID HYPERPLASIA; MULTIPLE CYCLE TREATMENT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GERMINAL CENTER; HUMANS; HYPERPLASIA; LYMPHOMA, FOLLICULAR; MICRORNAS; NEOPLASM STAGING; PROGNOSIS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TREATMENT OUTCOME;

EID: 84859460629     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.048132     Document Type: Article

References (52)

1. Vitolo U, Ferreri AJ, Montoto S. Follicular lymphomas. Crit Rev Oncol Hematol. 2008;66(3):248-261.
2. de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol. 2005;23 (26):6358-6363.
3. Tan D, Horning SJ. Follicular lymphoma: clinical features and treatment. Hematol Oncol Clin North Am. 2008;22(5):863-882, 8.
4. Schuler F, Hirt C, Dolken G. Chromosomal translocation t(14;18) in healthy individuals. Semin Cancer Biol. 2003;13(3):203-209.
5. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21): 2159-2169.
6. Janikova A, Tichy B, Supikova J, Stano-Kozubik K, Pospisilova S, Kren L, et al. Gene expression profiling in follicular lymphoma and its implication for clinical practice. Leuk Lymphoma. 2011;52(1):59-68.
7. Andreasson U, Eden P, Peterson C, Hogerkorp CM, Jerkeman M, Andersen N, et al. Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples. Am J Hematol. 2010;85(6): 418-425.
8. Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009;114(4):826-834.
9. Husson H, Carideo EG, Neuberg D, Schultze J, Munoz O, Marks PW, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood. 2002;99(1):282-289.
10. Pangault C, Ame-Thomas P, Ruminy P, Rossille D, Caron G, Baia M, et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia. 2010;24(12):2080-2089.
11. Calvo KR, Dabir B, Kovach A, Devor C, Bandle R, Bond A, et al. IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Blood. 2008;112(9):3818-3826.
12. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2): 215-233.
13. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350-355.
14. di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med. 2010;16(6):257-267.
15. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065-7070.
16. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-838.
17. Zhang J, Jima DD, Jacobs C, Fischer R, Gottwein E, Huang G, et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood. 2009; 113(19):4586-4594.
18. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793-1801.
19. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer. 2007;121(5):1156-1161.
20. Roehle A, Hoefig KP, Repsilber D, Thorns C, Ziepert M, Wesche KO, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 2008;142(5):732-744.
21. Lawrie CH, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S, et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009;13(7):1248-1260.
22. Li C, Kim SW, Rai D, Bolla AR, Adhvaryu S, Kinney MC, et al. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood. 2009;113(26):6681-6690.
23. Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW, et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood. 2010;116(23):e118-e127.
24. Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA. 2010;107(17):7904-7909.
25. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocytemonocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5(10):1171-1177.
26. Neelapu SS, Gause BL, Harvey L, Lee ST, Frye AR, Horton J, et al. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood. 2007; 109(12):5160-5163.
27. Chang H, Blondal JA, Benchimol S, Minden MD, Messner HA. p53 mutations, c-myc and bcl-2 rearrangements in human non- Hodgkin's lymphoma cell lines. Leuk Lymphoma. 1995;19(1-2):165-171.
28. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317-325.
29. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15-20.
30. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004;64 (9):3087-3095.
31. Tagawa H, Seto M. A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia. 2005;19(11):2013-2016.
32. Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol. 1998;152 (5):1107-1123.
33. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043): 828-833.
34. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9(4):405-414.
35. Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L, et al. MiRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 2002;16 (6):720-728.
36. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408(6811):433-439.
37. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000;60(14): 3689-3695.
38. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood. 2009;113(2):396-402.
39. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 2006;13(8):1351-1359.
40. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36 (6):320-328.
41. Angelin-Duclos C, Cattoretti G, Lin KI, Calame K. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp- 1 expression in vivo. J Immunol. 2000;165 (10):5462-5471.
42. Kuo TC, Shaffer AL, Haddad J, Jr., Choi YS, Staudt LM, Calame K. Repression of BCL-6 is required for the formation of human memory B cells in vitro. J Exp Med. 2007;204 (4):819-830.
43. Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol. 2008;26:133-169.
44. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol. 2004;173 (2):1158-1165.
45. Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006;203(2):311-317.
46. Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell. 2010;18(6): 568-579.
47. Calado DP, Zhang B, Srinivasan L, Sasaki Y, Seagal J, Unitt C, et al. Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell. 2010;18(6):580-589.
48. Nie K, Gomez M, Landgraf P, Garcia JF, Liu Y, Tan LH, et al. MicroRNA-mediated downregulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol. 2008;173(1):242-252.
49. Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, Gascoyne RD, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood. 2009;113 (16):3754-3764.
50. Yu X, Chen J. DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol. 2004;24(21):9478-9486.
51. Kumaraswamy E, Shiekhattar R. Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase. Mol Cell Biol. 2007;27(19): 6733-6741.
52. Gupta R, Sharma S, Sommers JA, Kenny MK, Cantor SB, Brosh RM Jr. FANCJ (BACH1) helicase forms DNA damage inducible foci with replication protein A and interacts physically and functionally with the singlestranded DNA-binding protein. Blood. 2007;110(7):2390-2398.